L. CONNOR, G. TEEHAN
138
Octreotide and albumin successfully reversed HRS. This
case also demonstrates that a patient failing one medical
therapy for H RS may respond to an altern ativ e or adjun c-
tive therapy; therefore these methods should be attemp-
ted to increase the patient’s chance of survival.
4. Conclusion
In conclusion, we have reported a case of type 1 HRS
that is successfully treated with vasopressin. There are
studies in Europe using terlipressin that have shown
some success, however, terlipressin is not available in
many countries. Since terlipressin is not available in the
United States, vasopressin is used as an alternative and is
successful in this reported case. We would advocate the
use of vasopressin where terlipressin is unavailable, par-
ticularly when other available treatments are failing to
reverse r e n a l failure.
REFERENCES
[1] C. Alessandria, A. Ottobrelli, W. Debernardi-Venon, L.
Todros, M. T. Cerenzia, S. Martini, et al., “Noradrenalin
vs Terlipressin in Patients with Hepatorenal Syndrome: A
Prospective, Randomized, Unblinded, Pilot Study,” Jour-
nal of Hepatology, Vol. 47, No. 4, 2007, pp. 499-505.
doi:10.1016/j.jhep.2007.04.010
[2] S. J. Munozo, “The Hepatorenal Syndrome,” Medical Cli-
nics of North America, Vol. 92, No. 4, 2008, pp. 813-837.
doi:10.1016/j.mcna.2008.03.007
[3] T. H. Kiser, R. Maclaren and D. N. Fish, “Treatment of
Hepatorenal Syndrome,” Pharmacotherapy, Vol. 29, No.
10, 2009, pp. 1196-1211. doi:10.1592/phco.29.10.1196
[4] P. Angeli, R. Volpin, G. Gerunda, R. Craighero, P. Roner,
R. Merenda, et al., “Reversal of Type 1 Hepatorenal Syn-
drome with the Administration of Midodrine and Octreo-
tide,” Hepatology, Vol. 29, No. 6, 1999, pp. 1690-1697.
doi:10.1002/hep.510290629
[5] E. Esrailian, E. R. Pantangco, N. L Kyulo, K. Q. Hu and
B. A. Runyon, “Octreotide/Midodrine Therapy Signifi-
cantly Improves Renal Function and 30-Day Survival in
Patients with Type 1 Hepatorenal Syndrome,” Digestive
Diseases and Sciences, Vol. 52, No. 3, 2007, pp. 742-748.
doi:10.1007/s10620-006-9312-0
[6] G. Pomier-Layragues, S. C. Paquin, Z. Hassoun, M. La-
fortune and A. Tran, “Octreotide in Hepatorenal Syn-
drome: A Ransomized Double-Blind, Placebo-Controlled,
Corssover Study,” Hepatology, Vol. 38, No. 1, 2003, pp.
238-243. doi:10.1053/jhep.2003.50276
[7] R. Moreau, F. Durand, T. Poy nard, C. Duhamel, J. P. Cer-
voni, P. Ichai, et al., “Terlipressin in Patients with Cir-
rhosis and Type 1 Hepatorenal Syndrome: A Retroepsc-
tive Mulitcenter Study,” Gastroenterology, Vol. 122, No.
4, 2002, pp. 923-930. doi:10.1053/gast.2002.32364
[8] C. Halimi, P. Bonnard, D. Bernard, P. Mathurin, A. Mo-
fredj, V. Martino, et al., “Effect of Terlipressin (Gly-
pressin) on Hepatorenal Syndrome in Cirrhotic Patients:
Results of a Multicentre Pilot Study,” European Journal
of Gastroenterology & Hepatology, Vol. 14, No. 2, 2002,
pp. 153-158. doi:10.1097/00042737-200202000-00009
[9] A. J. Sanyal, T. Boyer, G. Ga rcia-Tsao, F. Regenstein, L.
Rossaro, B. Appenrodt, et al., “A Randomized, Pros-
pective, Double-Blind, Placebo-Controlled, Trial of Terli-
pressin for Type 1 Hepatorenal Syndrome,” Gastroente-
rology, Vol. 143, No. 5, 2008, pp. 1360-1368.
doi:10.1053/j.gastro.2008.02.014
[10] P. Solanki, A. Chawla, R. Garg, R. Gupta, M. Jain and S.
K. Sarin, “Beneficial Effects of Terlipressin in Hepa-
torenal Syndrome: A Prospective, Randomized Placebo-
Controlled Clinical Trial,” Journal of Gastroenterology
Hepatology, Vol. 18, No. 2, 2003, pp. 152-156.
doi:10.1046/j.1440-1746.2003.02934.x
[11] Y. Narahara, H. Kanazawa, C. Sakamoto, H. Maruyama,
O. Yokosuka, S. Mochida, et al., “The Efficacy and Safe -
ty of Terlipressin and Albumin in Patients with Type 1
Hepatorenal Syndrome: A Multicenter, Open-Label, Ex-
plorative Study,” Journal of Gastroenterology, Vol. 47,
No. 3, 2011, pp. 313-320.
doi:10.1007/s00535-011-0485-8
[12] A. G. Testro, S. Wongseelashote, P. W. Angus and P. J.
Gow, “Long-Term Outcome of Patients Treated with Ter-
lipre ssi n fo r Ty pe s 1 a nd 2 He pa tor e na l Sy n dr ome , ” Jour-
nal of Gastroenterology and Hepatology, Vol. 23, No. 10,
2008, pp. 1535-1540.
doi:10.1111/j.1440-1746.2007.05176.x
[13] S. Neri, D. Pulvirenti, M. Malaguarnera, B. M. Cosimo,
G. Bertino, L. Ignaccolo, et al., “Terlipressin and Albu-
min in Patients with Cirrhosis and Type I Hepatorenal
Syndrome,” Digestive Diseases and Sciences, Vol. 53, No.
3, 2008, pp. 830-835. doi:10.1007/s10620-007-9919-9
[14] M. Martin-Llahi, M. N. Pepin, M. Guevara, F. Diaz, A.
Torre, A. Monescillo, et al., “Terlipressin and Albumine
vs. Albumin in Patients with Cirrhosis and Hepatorenal
Syndrome: A Randomized Study,” Gastroenterology, Vol.
134, No. 5, 2008, pp. 1353-1359.
doi:10.1053/j.gastro.2008.02.024
[15] R. Ortega, P. Gines, J. Uriz, A. Cardenas, B. Calahorra, D.
De Las Heras, et al., “Terlipressin Therapy with and
without Albumin for Patients with Hepatorenal Syndrome:
Results of a Prospective, Nonrandomized Study,” Hepa-
tology, Vol. 36, No. 4, 2002, pp. 941-941.
doi:10.1053/jhep.2002.35819
[16] M. Guevera, P. Gines, G. Fernandez-Esparrach, P. Sort, J.
M. Salmero, W. Jimenez, et al., “Reversibility of Hepa-
torenal Syndrome by Prolonged Administration of
Ornipressin and Plasma Volume Expansion,” Hepatology,
Vol. 27, No. 1, 1998, pp. 35-41.
doi:10.1002/hep.510270107
[17] V. Gulberg, M. Blizer and A. L. Gerbes, “Long-Term
Therapy and Retreatment of Hepatorenal Syndrome Type
1 with Ornipressin and Dopamine,” Hepatology, Vol. 30,
No. 4, 1999, pp. 870-875. doi:10.1002/hep.510300430
[18] T. H. Kiser, D. N. Fish, M. D. Obritsch, R. Jung, R.
MacLaren and C. R. Rarikh, “Vasopressin, Not Octreo-
tide, May Be Beneficial in the Treatment of Hepatorenal
Syndrome: A Retrospective Study,” Nephrology Dialysis
Transplantation, Vol. 20, No. 9, 2005, pp.1813-1820.
doi:10.1093/ndt/gfh930
Copyright © 2013 SciRes. OJNeph